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  The H9N2 subtype low pathogenic avian influenza is one of 
the most prevalent avian diseases worldwide, and was first 
documented in 1996 in Korea. This disease caused serious 
economic loss in Korea's poultry industry. 
  In order to develop an oil-based inactivated vaccine, a virus 
that  had  been  isolated  in  2001  (A/chicken/Korea/01310/ 
2001) was selected based on its pathogenic, antigenic, and 
genetic  properties.  However,  in  animal  experiments,  the 
efficacy of the vaccine was found to be very low without 
concentration of the antigen (2
7 to 2
10 hemagglutinin unit). 
In order to overcome the low productivity, we passaged the 
vaccine  candidate  virus  to  chicken  eggs.  After  the  20th 
passage, the virus was approximately ten times more productive 
compared with the parent virus. For the most part, the 
passaged virus maintained the hemagglutinin cleavage site 
amino acid motif (PATSGR/GLF) and had only three amino 
acid changes (T133N, V216G, E439D, H3 numbering) in the 
hemagglutinin molecule, as well as 18 amino acid deletions 
(55-72) and one amino acid change (E54D) in the NA stalk 
region. The amino acid changes did not significantly affect 
the  antigenicity  of  the  vaccine  virus  when  tested  by 
hemagglutination inhibition assay. Though not complete, 
the vaccine produced after the 20th passage of the virus 
(01310 CE20) showed good protection against a homologous 
and  recent  Korean  isolate  (A/chicken/Korea/Q30/2004)  in 
specific pathogen- free chickens.
  The vaccine developed in this study would be helpful for 
controlling the H9N2 LPAI in Korea.
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Introduction 
  Avian influenza virus (AIV) is an enveloped virus that 
belongs to the Orthomyxoviridae family and has an eight 
segmented, single stranded, negative sense RNA genome. 
Among the proteins encoded by the genome, there are two 
surface glycoproteins, hemagglutinin (HA) and neuram-
inidase (NA). AIV is classified into subtypes according to 
the combination of 16 HA and 9 NA molecules [10,26].  
  Among the many subtypes, the H9N2 AIV is thought to 
have originated from shorebirds and gulls [30], and rapidly 
spread to become one of the most prevalent diseases in 
domestic poultry worldwide. It has also caused serious 
economic loss in the poultry industry [5,16,17]. In Korea, 
the first H9N2 low pathogenic avian influenza (LPAI) 
outbreak occurred in 1996 [15]. Since 2000, and it has 
become endemic (especially in layer farms) [13,16]. Many 
studies have demonstrated that there are several distinct 
H9N2 AIV lineages, and indicated the Korean H9N2 
viruses formed a unique antigenic and phylogenetic cluster 
[13,15-18].
  Although immunization with this vaccine is not complete, 
it is one of the most promising control measures for the 
H9N2 LPAI to date. Some countries have used vaccines for 
H9N2 LPAI [5,17,22,29]; however, vast antigenic varia-
tions exist even within the same subtype, and it is very 
difficult to select a vaccine strain that is effective on the 
virus in current circulation. In addition, some isolates do 
not grow to a high enough titer in the embryonated chicken 
eggs (ECEs) to achieve efficient vaccine productivity [31].
  Korean animal health authorities took stamping-out and 
compensation control policies with regards to H9N2 LPAI 
when it occurred between 1996 and 1999. At that time, 
vaccines for subtypes of AIV, including H9N2 LPAI, were 
prohibited in Korea because they interfered in the 
discrimination of naturally infected birds from vaccinated 
birds. However, H9N2 LPAI became endemic, and the 
policy was not reliable enough to cover each outbreak. 68    Jun Gu Choi et al.
According to the 2004 Avian influenza standard operating 
procedures, Korean animal health authorities permitted the 
use of the vaccine for LPAI (especially the H9N2 subtype), 
and the Committee on the National AI Vaccine Campaign 
determined that using a single vaccine strain was the most 
effective strategy with which to simplify the H9N2 AI 
situation in Korea [7,20].
  In this study, we present the characterization of the Korean 
H9N2 LPAI vaccine strain, and evaluated the efficacy of 
the pilot vaccine in specific pathogen-free (SPF) chickens.
Materials and Methods
Viruses used in this study 
  All of the viruses were isolated by the National Veterinary 
Research and Quarantine Service  using routine diagnostic 
practices. The infectious tissue homogenates were inoculated 
in the allantoic cavity of  9-11 day old SPF ECEs (Lohmann 
Valo SPF Cuxhaven, Germany) according to standard 
procedures [27]. The first H9N2 isolate in Korea, A/ 
Chicken/Korea/MS96/1996 (MS96) [15] was used, and 
A/Chicken/Korea/99029/1999 (99029) and A/Chicken 
/Korea/01310/2001 (01310) were used as representative 
isolates of the 1999 and 2001 strain, respectively. The 2001 
strain was eventually chosen as the vaccine candidate. In 
order to test the antigenicity and the efficacy of the vaccine, 
a recent isolate, A/Chicken/Korea/Q30/2004 (04Q30), 
was used [16].
Pathogenicity  test  of  Korean  isolates  in  SPF  and 
commercial broiler chickens
  In order to determine the pathogenicity of the selected 
viruses in SPF and commercial broiler chickens, MS96, 
99029, and 01310 were inoculated via the intra-tracheal 
route in eight 7-week-old SPF chickens (10
6.5EID50/0.1 ml, 
10
5.6 EID50/0.1 ml, and 10
7.1 EID50/0.1 ml, respectively) 
and fifteen 12-week-old commercial broiler chickens 
(10
5.2 EID50/0.1 ml, 10
5.7 EID50/0.1 ml, and 10
5.0 EID50/0.1 
ml, respectively), which were confirmed to be free of 
antibodies against H9N2 AIV. In the experiment with SPF 
chickens, tracheal and cloacal swab samples were taken at 
3, 5, 7, and 9 days post-inoculation (dpi). The swab 
samples were suspended in 3 ml of gentamicin-PBS (1% 
gentamicin in PBS, pH 7.2), and were inoculated with 0.2 
ml of samples into three 9-11 day old SPF ECEsvia the 
allantoic cavity route. The inoculated broiler chickens 
were reared for 2 weeks, and the mortality was recorded. 
Antigenic relationship between Korean H9N2 AIVs
    After being propagated in ECEs, the viruses (MS96, 
99029, and 01310) were inactivated by incubating them 
with 0.1% formalin at 20
oC for 10 h. The inactivation was 
confirmed by injecting formalin-treated virus into the 
allantoic cavities of 10-day-old ECEs, two times serially. 
Virus inactivation was determined by hemagglutination 
negativity, using 1% chicken red blood cells. The inac-
tivated virus was emulsified with oil adjuvant (Montanide 
ISA 70 SEPPIC, France) at a ratio of 3：7, and wasinjected 
into eight 6-week-old SPF chickens. The antisera were 
obtained at 3 weeks after injection. In order to determine 
the antigenic relationship between the selected viruses, we 
performed a cross hemagglutination inhibition (HI) test 
with each of the antisera and virus antigens (four HA unit), 
and the r-value was subsequently calculated [2]. 
HA and NA gene sequencing for comparison with 
recent Korean isolates
  Viral RNA was extracted from infectious allantoic fluid 
using the Viral Gene-Spin Viral DNA/RNA extraction kit 
(iNtRON Biotechnology, Korea) and amplified using 
gene-specific primer sets by RT-PCR with a Qiagen one- 
step RT-PCR kit (Qiagen, USA) according to the method 
described by Hoffmann et al. [12]. The amplified product 
was excised from agarose gel and eluted using the 
GENECLEAN SPIN kit (Qbiogene, USA). The nucleotide 
sequences were analyzed by direct sequencing of the PCR 
products using ABI PRISM BigDye Terminator Cycle 
Sequencing Kits (Applied Biosystems, USA). The HA and 
NA gene nucleotide sequences of 01310 CE3 have been 
deposited in GenBank under accession number EU253561 
and EU253562, respectively.
  The nucleotide and deduced amino acid sequences of the 
HA and NA molecules were aligned by the Clustal W 
method with the MegAlign software (Lasergene 7.0; 
DNASTAR, USA). The similarity of the HA and NA amino 
acid sequences were compared with recently studied 
Korean H9N2 AIVs [16].
Efficacy testing of vaccine candidate virus accord-
ing to the antigen contents and virus passage in ECEs
  The selected vaccine candidate (01310 CE3, 2
7 HA unit) 
virus based on the above pathogenic, serologic, and molecular 
data (refer to the Results section) was used to prepare the 
vaccine according to the previously mentioned proced-
ures. The preparation of the high HA content vaccine (2
10 
HA unit) involved the concentration of the virus by 
centrifugation (18,000 rpm, 4 h; Beckman, USA). The 
vaccines were injected into ten 6-week-old SPF chickens 
via the intramuscular (IM) route. The serum samples were 
taken three weeks post-vaccination (wpv), and were 
followed by the performance of the HI test. The HI test 
results were analyzed using Student’s t-test. Statistical 
significance was set a priori at α = 0.05. The chickens were 
challenged with 01310 CE3 virus (10
6.0 EID50/0.1 ml) at 3 
wpv via the oral route. Next, oropharyngeal and cloacal 
swab samples were taken at 5 dpi for virus isolation. The 
Fisher’s exact test was performed to compare the virus 
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Table 1. Comparison of virus isolation and mortality of recent Korean H9N2 LPAIV
Virus
Virus isolation in SPF chickens*
Pathogenicity 
of commercial broiler chickens
† 3 dpi 5 dpi 7 dpi 9 dpi
op cl op cl op cl op cl
MS96 8/8 1/8 5/8 1/8 0/8 2/8 0/8 0/8 1/15 (6.7%)
99029 8/8 0/8 7/8 3/8 0/8 2/8 0/8 0/8 1/15 (6.7%)
01310 8/8 3/8 6/8 5/8 0/8 4/8 0/8 0/8 4/15 (26.7%)
Control 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/15 (0%)
*7-week-old SPF chickens were inoculated via the intra-tracheal route with MS96 (10
6.5EID50), 99029 (10
5.6EID50), and 01310 (10
7.1EID50): virus
isolation/total inoculated. 
†12-week-old AIV antibody-free commercial broiler chickens were inoculated via the intra-tracheal route with MS96 
(10
5.2 EID50), 99029 (10
5.7EID50), and 01310 (10
5.0EID50): number of dead/total inoculated (% mortality). op: oropharyngeal, cl: cloacal.
  In order to recover the highly growing vaccine virus in 
ECEs, the vaccine candidate virus was serially passaged 
through 9- to 11-day-old SPF ECEs and selected with high 
HA titer using chicken red blood cells. The passage number 
in ECEs was indicated as CE X (X stands for passage 
number) after the virus name.
Pathogenicity test of the selected vaccine virus in 
SPF ECEs and chickens
  In order to test the changes in the pathogenicity of the 
passaged vaccine viruses in chicken eggs, the viruses 
(CE5, CE10, CE15, CE20, and CE40) were diluted in PBS 
and inoculated in the allantoic cavities of 10-day-old SPF 
ECEs. In addition, the mortality was checked after 48 h of 
incubation.
  For the pathogenicity test of the selected vaccine virus in 
chickens, eight 6-week-old SPF chickens were intra- 
venously inoculated with 0.2 ml of 1/10 diluted virus, and 
we noted the mortality for 10 days according to standard 
procedures [31]. 
  Antigenicity  testing  and  the  optimum  growth 
condition of the vaccine virus
  The vaccines of the antigenicity test were prepared with 
01310 CE6, CE20, and CE40 viruses. In addition, the HA 
titers of the viruses were adjusted to 2
9 HA units. Eight 
6-week-old SPF chickens were then vaccinated at 0.5 
ml/chickenvia the IM route. After vaccination, serum 
samples were taken at 3 wpv, and the HI assay was then 
performed with the MS96 CE3, 01310 CE20, and 04Q30 
CE3 viruses. A one-way ANOVA test was subsequently 
performed.
  In order to determine the optimum growth conditions of 
the vaccine strain in ECEs, the virus was serially diluted 
10-fold with 1% gentamicin-PBS (10
-3-10
-7), and was 
inoculated into 60 SPF ECEs. At 8, 16, 24, 32, 40, and 48 
hours after incubation, 10 eggs were harvested during each 
dilution and the HA titer was determined with 1% chicken 
red blood cells [27]. 
  Vaccine efficacy test
  The vaccine was prepared with the 01310 CE20 (2
10 HA 
unit) strain as per the procedures mentioned in the 
Materials and Methods section, and was injected at a 
concentration of 0.5 ml/chicken via the intramuscular 
route (thigh muscle) into each of eight 6-week-old SPF 
chickens. Three weeks after vaccination, the parent virus 
(01310 CE3, 10
5.5 EID50/0.1 ml) and recent Korean isolate 
(04Q30 CE3, 10
5.5 EID50/0.1 ml) were challenged intranasally. 
To isolate the challenged virus, oropharyngeal and cloacal 
swab samples were taken at 1, 3, and 5 dpi from each 
chicken and suspended in 3 ml of gentamicin-PBS. The 
samples were subsequently inoculated into three 9- to 
11-day-old SPF ECEs respectively, followed by 
assessment of the virus growth from the allantoic fluids. At 
5 dpi, the chickens were sacrificed and the various tissues 
were taken with different scissors in order to prevent 
contamination. Next, the 10% (w/v) tissue homogenates 
were tested for viral growth in three 9- to 11-day-old SPF 
ECEs. In order to titrate the virus from various tissues, 
tissue homogenates were pooled in a group of equal 
volume, and were then titrated using SPF ECEs.
Results
Vaccine candidate selection
  In order to select the vaccine candidate, we chose the 
MS96, 99029, and 01310 viruses as the representative 
viruses of the year. In addition, we compared the virus 
replication potency and pathogenicity for SPF and 
commercial broiler chickens. For the SPF chickens, all of 
the viruses had a zero mortality rate; however, the viruses 
were isolated at 3 to 5 dpi from oropharyngeal swab 
samples, and 3 to 7 dpi from cloacal swab samples. At 5 
dpi, the MS96, 99029, and 01310 viruses were isolated 
from 5/8, 7/8, and 6/8 oropharyngeal swab samples and 70    Jun Gu Choi et al.
Table 3. Comparison of vaccine efficacy according to the antigen 
content
Antigen 
content
(HA unit)
HI titer at 
3 weeks post 
vaccination
Virus isolation at 5 dpi
†
Oropharyngeal
swab
Cloacal
swab
01310 CE3 (2
7) 8.2 ± 0.6*   7/10
‡  9/10
‡
01310 CE3 (2
10) 8.8 ± 0.4*   1/10
‡   3/10
‡
Control − 10/10 10/10
*Mean ± SD of the titer analyzed with the Student’s t-test, α = 0.05, p
= 0.022. 
†The chickens were challenged intranasally with the homolo-
gous virus (01310 CE3, 10
6.0EID50/0.1 ml): virus isolation / total 
tested.  
‡Fisher’s exact test, p = 0.020, respectively.
Table 4. Comparison of virus titer and mortality in ECEs and SPF
chickens of passaged vaccine candidate
Passage 
  No.
HA titer 
(log2)
Virus titer
(log10EID50/0.1 ml)
Mortality 
in ECEs*
Mortality in
SPF chicken
†
CE5 7 7.5 3/10 nt
CE7 8 nt
‡ nt nt
CE10 9 8.5 2/10 nt
CE15 10 8.4 2/10   nt
CE20 10 8.7 6/10 0/8
CE30 10 nt nt nt
CE40 10 nt 5/10 nt
*Mortality at 2 dpi incubation time. The viruses were inoculated at
10
4.5EID50/0.1 ml each. 
†The 8 SPF chickens were intravenously 
inoculated with 0.2 ml of 1/10 diluted (10
7.7EID50/0.1 ml) infectious
allantoic fluid and observed for 10 days.  
‡nt: not tested.
Table 2. Antigenic relationship between Korean isolates
Antiserum
Virus
MS96 99029 01310
MS96 169* (1.00
†)   60 (0.73) 274 (0.90)
99029 239 158 (1.00) 181 (0.61)
01310 274 181 549 (1.00)
*Mean HI titer from 8 chickens. 
†r-value, r = (r1 × r2)
1/2. r1 = heterolo-
gous titer with virus 2 / homologous titer with virus 1. r2 = heterolo-
gous titer with virus 1 / homologous titer with virus 2.
1/8, 3/8, and 5/8 cloacal swab samples, respectively. 
Furthermore, in commercial broiler chickens, the 01310 
strain showed a 26.7% mortality rate, whereas a 6.7% 
mortality rate was recorded for each of the other two 
viruses (Table 1).
    To elucidate the antigenic relationship between the 
selected Korean isolates, the r-value was calculated with a 
cross HI titer between the viruses. The values ranged from 
0.61 to 1.00, with no significant differences between the 
viruses (Table 2). 
  Based on our pathogenic and serologicdata, we chose the 
01310 virus as a vaccine candidate. Moreover, when we 
compared the HA and NA amino acid sequences deduced 
by nucleotide sequences, the 01310 CE3 virus was found 
to have 95.5-98.6% and 94.6-98.5% similarity with the 
recent Korean H9N2 AIVs isolated from 2002 to 2004, 
respectively (data not shown).
Efficacy  of  the  selected  vaccine  candidate  virus 
according to the antigen contents
  In order to elucidate the efficacy of the vaccine candidate 
virus, ten SPF chickens were immunized with different 
antigen contents. Chickens immunized with a high antigen 
vaccine (2
10 HA unit) showed a similar but statistically 
significant (p ＜ 0.05) antibody titer compared to the low 
antigen content (2
7 HA unit) vaccine (Table 3). In addition, 
in the low antigen content vaccine group, the challenged 
viruses were recovered from 7/10 and 9/10 chickens from 
oropharyngeal and cloacal swab samples at 5 dpi, 
respectively. It was believed that the vaccine was not 
effective to protect against viral shedding. However, in 
high antigen content groups, the challenged virus was 
isolated from 1/10 or 3/10 oropharyngeal/cloacal swab 
samples, respectively. Although neither of the vaccines 
were able to completely protect against viral shedding, the 
high antigen content vaccine was more effective than the 
low antigen content vaccine upon comparison of the virus 
recovery rate in the oropharyngeal/cloacal swab samples 
(p = 0.02, respectively) (Table 3).
Biological characteristics of the vaccine virus
  The vaccine candidate virus (01310 CE3) grew in ECEs at 
around 2
7 HA units and about 10
7.0 EID50/0.1 ml, as did 
most of the field isolates (personal observation, data not 
presented), and we were not able to determine the expected 
vaccine efficacy with unconcentrated antigen (Table 3). 
Therefore, we attempted to get highly growing phenotyped 
viruses through egg passage. When the 01310 strain was 
passaged in SPF ECEs as a vaccine candidate, the virus titer 
increased with each ECE passage (Table 4). After the 15th 
passage in ECEs, the virus titer showed 2
10 HA units stably; 
this was approximately 10 times greater than that of the 
parent virus. Moreover, the 20th passaged virus showed the 
highest titer, 10
8.7 EID50/0.1 ml (Table 4). As shown in Fig. 1, 
the 01310 CE20 showed the highest HA titer when 
inoculated with 10
4.7 EID50/0.1 ml and incubated for 32 
hours. The mean HA titer at that point was 9.7 ± 0.5 (log2).
  However, as the 01310 virus was passaged in SPF ECEs, 
the mortality of the chicken eggs also increased. During 48 Inactivated vaccine for H9N2 LPAI in Korea    71
Table 5. Immunogenicity and comparison of serological 
relationship with Korean isolates
Antisera
HI titer (mean ±SD, log2)
with homologous / heterologous Ag
MS96 01310, CE20 04Q30, CE3
01310, CE6 −
‡ 7.8 ± 0.5* −
01310, CE20 8.8 ± 0.7
†  8.3 ± 0.7*† 9.1 ± 1.0
†
01310, CE40 − 8.4 ± 0.7* −
Control 0.0 0.0 0.0
The values were analyzed with a one-way ANOVA test. α = 0.05, *p
= 0.12, 
†p = 0.15. 
‡ not tested.
Table 6. Vaccine efficacy test of the 01310 CE20 strain against the parent virus (01310 CE3) and the recent Korean isolate (04Q30 CE3)
Challenge
virus Vaccination*
Oropharyngeal (op) / 
cloacal (cl) swab sample
† Tissue homogenate (10% w/v)
‡
1dpi 3 dpi 5 dpi
Brain Trachea Lung Spleen Kidney
Cecal 
Tonsil op cl op cl op cl
01310
CE3
+ 0/7 0/7 0/7  0/7 0/7  0/7  0/7  (nt) 0/7 (0) 0/7 (0) 0/7 (0) 0/7 (0) 0/7 (0)
− 2/8  0/8 7/8  0/8 7/8 6/8  0/8 (nt) 5/8 (10
1.4) 0/8 (0) 1/8 (0) 0/8 (0) 4/8 (10
5.4)
04Q30
CE3
+ 2/8 0/8 2/8 0/8 0/8 0/8 0/8 (nt) 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0)
− 6/8 0/8 8/8 3/8 8/8 5/8 0/8 (nt) 8/8 (10
4.4)6 / 8  ( 1 0
2.0) 2/8 (0) 2/8 (10
1.6)5 / 8  ( 1 0
6.0)
*Vaccine prepared as described in Materials and Methods with 01310 CE20 (2
10 HA unit) and vaccinated intramuscularly at 0.5 ml/chicken.
†Virus isolation / total tested. 
‡Tissues were taken at 5 dpi, virus isolation / total tested (virus titers of the pooled samples, EID50/0.1 ml), nt:
not tested.
Fig. 1. Growth curves of the vaccine strain (01310 CE20) 
according to the virus titer (log10EID50/0.1 ml) of the inocula.
h of incubation, sixof ten eggs infected with the 01310 
CE20 virus were dead, whereas, two to three of ten eggs 
were dead due to the CE15 virus or other less passaged 
viruses. In spite of increased mortality in chicken eggs, the 
CE20 virus showed no mortality for the intravenous 
challenge experiment with SPF chickens, and was thought 
to maintain the LPAI characteristics according to the OIE 
criteria [31] (Table 4).
Molecular characterization of HA and NA gene of 
the vaccine virus
  Upon comparison of HA amino acid sequences of the 
01310 CE3, CE20, and CE40 to HA cleavage (PATSGR/ 
GLF), receptor binding (183H, 190E, 226Q, 228G), and 
potential glycosylation sites (158N), we found no changes 
(even in the CE40 passaged virus). HA has only three 
amino acid changes in the CE20 virus (T133N, V216G in 
HA1 region, and E439D in HA2 region), and an additional 
change occurred (L531F) in the CE40 virus (H3 
numbering). In the NA molecule, the CE20 and CE40 
viruses have an 18 amino acid deletion in the stalk region 
(55-72); both of these viruses also contain a change in one 
amino acid (E54D) (data not shown).
Antigenicity of the vaccine virus 
  As shown in Table 5, the HI titers (log2) of the 01310 
CE20 antisera with MS96 CE3, 01310 CE20, and the 
recent isolate, 04Q30 CE3, were 8.8 ± 0.5, 8.3 ± 0.5, and 
9.1 ± 1.0, respectively. Moreover, the HI titers of antisera 
of 01310 CE6, CE20, and CE40 with the homologous Ag 
(01310 CE20) were 7.8 ± 0.2, 8.3 ± 0.5, and 8.4 ± 0.6, 
respectively. One-way ANOVA comparison of the HI titers 
revealed no significant difference.
Vaccine efficacy test
  For the vaccine efficacy test, eight 6-week-old chickens 
were vaccinated with 01310 CE20 and challenged after 3 
weeks with homologous parent vaccine virus (01310 CE3) 
or the recent Korean isolate (04Q30 CE3). Moreover, swab 
samples were taken at 1, 3, and 5 dpi, and were tested for 
virus isolation. The highest isolation number was obtained 72    Jun Gu Choi et al.
for 5 dpi in both of the unvaccinated groups. The 
oropharyngeal and cloacal swab samples taken at 5 dpi 
showed isolation of 7/8 and 6/8 for the 01310 CE3 group 
and 8/8 and 5/8 for the 04Q30 CE3 group, respectively. On 
the other hand, the viruses for the vaccinated group, which 
were isolated only from the 04Q30 challenge group, 
showed isolation of 2/8 oropharyngeal swab samples taken 
at 1 and 3 dpi (Table 6).
  In the tissue samples taken at 5 dpi, the challenged viruses 
were not isolated from the vaccinated group, whereas for 
the unvaccinated group, the 01310 CE3 virus was isolated 
from trachea (5/8, 10
1.4 EID50/0.1ml), spleen (1/8, 0), and 
cecal tonsil (4/8, 10
5.4), but not from the brain, lung, or 
kidney. In addition, the 04Q30 CE3 virus was isolated from 
the trachea (8/8, 10
4.4), lung (6/8, 10
2.0), spleen (2/8, 0), 
kidney (2/8, 10
1.6), and cecal tonsil (5/8, 10
6.0), but not from 
the brain. In both of the unvaccinated groups, the cecal 
tonsil showed the highest viral titer (Table 6). 
Discussion
  Since the first H9N2 LPAI outbreak in 1996, numerous 
cases have occurred in Korea, and the H9N2 subtype LPAI 
has become one of the greatest problems of the country’s 
poultry industry (especially for breeders and commercial 
layers) [13,16].
  It is worth noting that avian influenza viruses in their 
natural hosts, which include wild waterfowl, gulls, and 
shorebirds, have shown a high rate of genetic conservation. 
Transmission to other species such as poultry may cause 
significant amounts of genetic and antigenic changes 
[12,16-18,25,30]. For a vaccine to be effective, it is necessary 
that the strain has genetic and antigenic traits similar to 
those of the currently circulating field viruses. Therefore, it 
is very important to choose the most effective vaccine 
strain to prevent the current circulation of viruses. Some 
countries such as China [17], Pakistan [22], Iran [29], and 
Israel [5] have already begun the use of H9N2 LPAI 
vaccines. Because of the above mentioned reasons, each of 
the countries used their own vaccine strains to control the 
H9N2 LPAI. Based on the properties of AIV, we chose a 
candidate vaccine virus with a relatively high pathogenicity 
in chickens, as well as antigenic and genetic similarity to 
recent field isolates. Despite this, the vaccine efficacy test 
of the selected virus (01310), according to the antigen 
contents using unconcentrated antigen (2
7 HA unit), 
showed unsatisfactory protective results compared with 
the high antigen content vaccine. As for other vaccines, the 
antigen contents are the critical component of an effective 
vaccine. Despite this, the antigen concentration requires an 
increased vaccine production cost, which may be a 
problem in terms of AI vaccination at the farm level. In 
order to overcome the low titer of the vaccine candidate 
strain, the virus was passaged in chicken eggs. Consequent 
to the passages of the selected virus, the vaccine strain may 
have approximately ten times higher titers than the parent 
virus. Moreover, the rapid growth property and 
antigenicity of the virus were maintained through the 
fortieth passage. 
  In order to determine the optimum inactivation condi-
tions, the virus was incubated in 0.1% formalin at 37
oC. 
However, under these conditions, the HA titer of the virus 
was decreased by four times, even after 1 h of incubation 
(data not shown). HA is considered the major antigenic 
protein, and a decreased HA titer signifies decreased 
antigenicity. Therefore, the virus was treated at a lower 
temperature (20
oC) and the inactivation conditions were 
determined. At 20
oC, a 6-hour incubation time is enough to 
inactivate the virus and not show any HA titer changes, 
even after 12 h of incubation (data not shown).
  Although the HA cleavage site (PATSGR/GLF) was well 
conserved and showed low pathogenic characteristics in 
the vaccine strain (01310 CE20), the pathogenicity in ECEs 
was increased. Therefore, we tested the pathogenicity of 
the vaccine strain in SPF chickens. When the vaccine strain 
was injected into SPF chickens via the intravenous route 
according to the standard procedures [31], no mortality 
was observed in the SPF chickens. Moreover, the vaccine 
strain has an amino acid sequence consistent withavian 
virus characteristics at the receptor binding site (Gln226), 
which confers a high binding affinity to the 2, 3-linked 
sialic acid (SA) moieties (abundant in avian and horses) 
rather than the 2, 6-linked SA moieties found in most 
mammals [19]. Although it is not sufficient, the patho-
genicity for chickens and the low binding potential to 2, 
6-linked SA secured the safety of the vaccine strain with 
regard to human infection (especially in vaccine producers). 
    We observed three amino acid changes (Thr133Asn, 
Val216Gly, Glu439Asp) compared to the parent virus 
(01310 CE3) in the HA molecules. The changed amino 
acids have similar traits (Thr and Asn have a polar 
uncharged side chain, Val and Gly have a non-polar side 
chain, Glu and Asp are acidic amino acids) with the parent 
sequences. However, the Thr133Asn change created an 
additional potential N-linked glycosylation site located on 
the right edge of the receptor binding pocket [11]. Many 
studies have demonstrated that the addition of oligosac-
charides to the HA molecule changes the antigenicity of the 
virus [1,6,24,28]. However, in this study, the additional 
potential glycosylation site did not significantly affect the 
antigenicity of the vaccine strain.
  A number of studies have shown that a balance between 
the HA and NA activities is critical for the efficiency of 
viral growth in host cells [3,4,8,21,23]. In this study, the 
HA molecule of the vaccine virus (01310 CE20) has a 
potential glycosylation site on amino acid 158, and 
represents an additional potential glycosylation site in the 
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to the 18 amino acid deletion in the NA stalk region. It is 
not clear that such changes exclusively affect the high 
growth trait of the vaccine virus. Further studies would be 
needed to clarify the mechanism for the modification of 
this trait of the vaccine virus as the virus is being passaged 
in ECEs. In addition, it is believed that the 54 base pair 
deletion in the NA gene could be used as a vaccine strain 
marker to identify the vaccine virus. 
    Although the vaccine candidate virus was isolated in 
2001 and may be thought of as outdated, the virus showed 
high antigenic and genetic similarity to the recent Korean 
H9N2 LPAIVs. Moreover and most importantly, the vaccine 
efficacy test with SPF chickens showed that the vaccine 
candidate sufficiently protected the chickens from the 
virus [both the homologous (01310 CE3) and recent 
Korean isolate (04Q30)] (Table 6). The challenge virus 
was recovered from only two of the eight oropharyngeal 
swab samples taken at 1 and 2 dpi in the 04Q30 challenged 
group, respectively, whereas the challenged virus was 
recovered throughout the experiment and peaked at 5 dpi 
for the unvaccinated group. Moreover, in subsequent repeated 
animal experiments, we were able to obtain a reliable and 
constant virus recovery rate for the cecal tonsil (data not 
shown). So far, no standards exist for the evaluation of the 
inactivated AI vaccine efficacy. Based on the animal 
challenge experiments (the experiments conducted in our 
lab and the data not presented), the Committee on the 
National AI Vaccine Campaign determined that the 
minimum efficacy requirements for inactivated H9N2 
LPAI vaccines was a greater than 80% inhibition of the 
virus recovery rate in cecal tonsils of the vaccinated group, 
compared to the rate observed in unvaccinated chickens at 
5 dpi.
  Despite these requirements, AIV is a continuously evolving 
virus [9,13,16,17,25,30], and as shown in this study, the 
inactivated LPAI vaccine cannot completely protect 
against viral infection and shedding into the environment. 
In addition, immune pressures (such as vaccination) have 
resulted further complication of the AI situation [14]. 
Therefore, the Korean government has conditionally 
issued a vaccine production license according to the 
following stipulations: 1) The vaccine producers have to 
record all selling activity and submit records to the Korean 
animal health authority (NVRQS) as requested; 2) 20 to 30 
sentinel birds must be deployed in every vaccinated 
poultry farm, and the sera from 10% of the vaccinated birds 
must be tested with those of unvaccinated sentinel birds in 
order to monitor LPAI infection at least twice a year, and 
the results must be submitted to the NVRQS. In addition, 
as a separate complementary measure, active surveillance 
has been deployed to monitor any changes in the 
antigenicity of the current circulating H9N2 LPAIV; if 
changes in antigenicity are detected, the vaccine virus will 
be changed to a more appropriate virus.
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